A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders

Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Tomohiko Mukai,1,2 Masatsugu Moriwaki,1,2 Hideaki Tabuse,3 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, 3Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kishi T, Matsuda Y, Matsunaga S, Mukai T, Moriwaki M, Tabuse H, Fujita K, Iwata N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Aripiprazole Blonanserin Schizophrenia Efficacy Safety Randomized trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9b7ada8e7b5f463f8984ded9453c6436
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b7ada8e7b5f463f8984ded9453c6436
record_format	dspace
spelling	oai:doaj.org-article:9b7ada8e7b5f463f8984ded9453c64362021-12-02T04:13:36ZA randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders1178-2021https://doaj.org/article/9b7ada8e7b5f463f8984ded9453c64362016-11-01T00:00:00Zhttps://www.dovepress.com/a-randomized-trial-of-aripiprazole-vs-blonanserin-for-the-treatment-of-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Tomohiko Mukai,1,2 Masatsugu Moriwaki,1,2 Hideaki Tabuse,3 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, 3Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194).Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events.Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups.Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia. Keywords: aripiprazole, blonanserin, schizophrenia, efficacy, safety, randomized trialKishi TMatsuda YMatsunaga SMukai TMoriwaki MTabuse HFujita KIwata NDove Medical PressarticleAripiprazoleBlonanserinSchizophreniaEfficacySafetyRandomized trialNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 12, Pp 3041-3049 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aripiprazole Blonanserin Schizophrenia Efficacy Safety Randomized trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Aripiprazole Blonanserin Schizophrenia Efficacy Safety Randomized trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kishi T Matsuda Y Matsunaga S Mukai T Moriwaki M Tabuse H Fujita K Iwata N A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
description	Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Tomohiko Mukai,1,2 Masatsugu Moriwaki,1,2 Hideaki Tabuse,3 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, 3Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194).Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events.Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups.Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia. Keywords: aripiprazole, blonanserin, schizophrenia, efficacy, safety, randomized trial
format	article
author	Kishi T Matsuda Y Matsunaga S Mukai T Moriwaki M Tabuse H Fujita K Iwata N
author_facet	Kishi T Matsuda Y Matsunaga S Mukai T Moriwaki M Tabuse H Fujita K Iwata N
author_sort	Kishi T
title	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
title_short	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
title_full	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
title_fullStr	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
title_full_unstemmed	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
title_sort	randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/9b7ada8e7b5f463f8984ded9453c6436
work_keys_str_mv	AT kishit arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsuday arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsunagas arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT mukait arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT moriwakim arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT tabuseh arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT fujitak arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT iwatan arandomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT kishit randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsuday randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT matsunagas randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT mukait randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT moriwakim randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT tabuseh randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT fujitak randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders AT iwatan randomizedtrialofaripiprazolevsblonanserinforthetreatmentofacuteschizophreniaandrelateddisorders
_version_	1718401388525912064

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders

Ejemplares similares